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ABSTRACT
Objective. This study was conducted to assess the dose proportionality, safety, and tolerability of fentanyl buccal
tablet (FBT) in Japanese volunteers.
Methods. Healthy, opioid-naive Japanese adults received single-dose FBT 100, 200, 400, and 800 mg in a random-
ized, open-label, crossover fashion. Naltrexone was given to minimize the opioid effects of fentanyl. Peak serum
fentanyl concentration (Cmax), time to Cmax (tmax), area under the serum fentanyl concentration-time curve (AUC)
from time 0 to inﬁnity (AUC0–•), and AUC from 0 to the last quantiﬁable concentration (AUC0–last) were summarized
using descriptive statistics. Dose proportionality was claimed if the ln-ln plots of Cmax, AUC0–•, and AUC0–last vs. dose
were linear and the 90% conﬁdence intervals (CI) of the slopes were within 0.8927 and 1.1073. The safety population
comprised volunteers who received 1 FBT.
Results. Twenty-ﬁve volunteers were enrolled, 23 were included in the safety population (mean age 35.3 years), and
19 completed the study. The assessment of dose proportionality did not meet the statistical criteria (slope [90% CI]:
0.9118 [0.8601, 0.9635] for Cmax, 1.0756 [1.0377, 1.1136] for AUC0–•, and 1.0992 [1.0677, 1.1307] for AUC0–last).
However, the increase in systemic exposure with dose appeared linear, and a post hoc analysis of partial AUCs from
time 0 to 8, 12, 18, and 24 hours supported dose proportionality. Median tmax of 90 minutes (range 30–180 minutes)
was independent of dose. Adverse events (AEs) were mild or moderate. The most frequent AEs were nausea (N = 9),
dizziness (N = 8), headache (N = 6), somnolence (N = 6), dyspepsia (N = 5), and vomiting (N = 3). No application-
site or serious AEs were reported.
Conclusions. Systemic exposure to FBT was approximately dose proportional across the range 100 mgt o8 0 0mgi n
healthy Japanese adults. Adverse events were mild or moderate.
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Introduction
F
entanyl buccal tablet (FBT; FENTORA
®,
Cephalon, Inc., Frazer, PA, USA) is approved
for marketing in the United States for the man-
agement of breakthrough pain in patients with
cancer who are already receiving and who are tol-
erant to around-the-clock opioid therapy for their
underlying persistent cancer pain [1]. FBT
employs OraVescent
® technology to enhance the
rate and extent of fentanyl absorption across the
buccal mucosa [2].
Assessment of dose proportionality can help
predict patients’ response to changes in dose.
Drugs that exhibit linear pharmacokinetics usually
provide a predictable systemic exposure when a
dose is increased or decreased. The objective of
this study was to investigate the pharmacokinetics, This study was sponsored by Cephalon, Inc., Frazer, PA.
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tolerability of FBT 100 mgt o8 0 0mg in healthy
Japanese volunteers. The study was conducted to
support the submission of a new drug application
for FBT in Japan.
Methods
Study Population
Healthy Japanese men and women living in the
United States, aged 20 to 55 years with a body
mass index of 17.6 to 29 kg/m
2, were eligible for
the study if they had clinically normal ﬁndings
based on medical history, physical examination,
and laboratory tests (serum chemistry, hematol-
ogy, urinalysis, human immunodeﬁciency virus
test screen, hepatitis B surface antigen screen, and
hepatitis C antibody screen). Women of childbear-
ing potential were required to have a negative
serum pregnancy test result and to practice a reli-
able form of contraception or abstinence for 2
weeks before screening and throughout the study.
Eligible volunteers were required to have a nega-
tive urine drug test result (cocaine, opiates, can-
nabinoids, alcohol) at the time of screening and at
check-in for each study phase. Volunteers were
excluded if they had smoked more than 10 ciga-
rettes per day within 3 months of the ﬁrst sched-
uled dose of FBT. Volunteers were prohibited
from using over-the-counter medications (includ-
ing herbal supplements) and prescription medica-
tions within 7 days and 14 days, respectively, of the
ﬁrst dose of FBT and throughout the study. Drugs
or substances known to strongly induce cyto-
chrome P450 (CYP) enzymes were prohibited
within 30 days of the start of the study; drugs or
substances known to strongly inhibit CYP
enzymes were prohibited within 10 days of the
start of the study.
Study Design
This study was conducted at a single center in
Hawaii (Radiant Research, Honolulu). The proto-
col was approved by the Institutional Review
Board of Quorum Review, Inc. All volunteers pro-
vided written informed consent.
In this open-label, randomized, crossover study,
volunteers received a single dose of FBT 100 mg,
200 mg, 400 mg, and 800 mg in 4 treatment phases
separated by at least 7 days of washout. These
doses were selected because previous pharmacoki-
netics studies indicated that FBT 100 mgt o8 0 0mg
would result in serum fentanyl concentrations
sufﬁcient to achieve study objectives with minimal
risk to healthy volunteers administered naltrexone
[3]. Because healthy volunteers are not opioid
tolerant, oral naltrexone hydrochloride 50 mg
(Barr Pharmaceuticals, Inc., Pomona, NY) was
given 15 hours and 3 hours before FBT adminis-
tration in all study phases to minimize the opioid
receptor–mediated effects of fentanyl. Naltrexone
hydrochloride was also given 12 hours after FBT
administration for the treatment phases with FBT
400 mg and 800 mg. Coadministration of naltrex-
one with fentanyl would not be expected to affect
the pharmacokinetics of fentanyl because fentanyl
is a substrate of CYP3A4 [4], and naltrexone is not
an inhibitor or inducer of CYP3A4 [5].
Fasting volunteers self-administered FBT by
placing the tablet buccally above a molar tooth
and allowing it to dissolve for 10 minutes. If
any portion of the tablet remained at that time,
volunteers were instructed to gently massage the
adjacent cheek area for 5 minutes to facilitate dis-
solution. (It is important to note that massage is no
longer recommended in the FBT prescribing
information [1].) Any tablet material remaining
after the 5-minute massage (as veriﬁed by study
center personnel) was allowed to disintegrate on
its own.
DwellTime Assessment
Dwell time, deﬁned as the time between tablet
placement and complete disappearance of tablet
residue, was visually veriﬁed and recorded by study
personnel.
Sample Collection
Venous blood samples (5 mL) were collected
before and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10,
12, 18, 24, 30, and 36 hours after placement of
FBT for serum fentanyl assay. Samples were
allowed to clot at room temperature. They were
then centrifuged at 2,500 revolutions per minute
for 15 minutes at 4°C to separate the serum, which
was transferred to clear polypropylene containers,
and stored at -20°C until assayed.
Analytical Methods
Serum samples were analyzed for fentanyl con-
centrations using a validated assay for high-
performance liquid chromatography with tandem
mass spectrometric detection (HPLC-MS/MS;
PE Sciex API 3,000 mass spectrometer). The
analyte and internal standard (d5-fentanyl) were
extracted from serum by liquid-liquid extraction
under basic conditions. Serum extracts were
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tion onto the HPLC-MS/MS. Detection was
accomplished using multiple-reaction monitoring
in positive ion mode. The linear range for the
assay was 10 to 5,000 pg/mL (0.01–5.0 ng/mL),
and the lower limit of quantitation was 50 pg/mL
(0.05 ng/mL). The interassay precision (% coefﬁ-
cient of variation) of quality control samples was
3.6%, and interassay accuracy ranged from
96.3% to 100.7%.
Pharmacokinetic Analysis
The maximum serum fentanyl concentration
(Cmax) was obtained by direct inspection of the data
without interpolation; tmax was deﬁned as the time
to reach Cmax. The area under the serum fentanyl
concentration-time curve (AUC) from time zero
to the time of the last quantiﬁable concentration
(Clast; AUC0–last) was determined using linear
trapezoidal summation. AUC from time zero
extrapolated to inﬁnity (AUC0–•) was calculated as
AUC0–last + Clast/lz, where lz was the terminal
phase elimination rate constant (from the negative
slope of the linear regression of log concentration
over time in a terminal phase that included at least
3 time points). AUC0–• values were dropped from
the analysis if the extrapolated area was >20% of
the total AUC0–•. Half-life (t 1
2) was calculated as
ln(2)/lz. Serum fentanyl concentrations below the
limit of detection were set to zero if they occurred
at the beginning of the proﬁle and were considered
missing if they occurred at the last measurable
concentration. Pharmacokinetic parameters for
fentanyl were estimated using non-compartmental
methods with WinNonlin
® Professional software
Version 4.0 or higher (Pharsight Corporation,
Mountain View, CA).
Because the analysis could be biased by the fen-
tanyl concentrations that fell below the limit of
detection at the low doses, post hoc analyses were
performed to assess dose proportionality using
partial AUCs, which were calculated at 8 hours
(AUC0–8), 12 hours (AUC0–12), 18 hours (AUC0–18),
and 24 hours (AUC0–24). Calculation of these
AUCs minimized the percentage of the extrapo-
lated area contributing to values for AUC0–•.
Safety andTolerability Assessments
The safety and tolerability of FBT was assessed by
monitoring adverse events (AEs), clinical labora-
tory test results, vital signs, ECGs, and physical
examination ﬁndings, including evaluation of the
oral mucosa. Clinical laboratory tests (serum
chemistry, hematology, and urinalysis), physical
examination including vital signs, and a 12-lead
ECG were performed at screening and the end of
the study. Vital signs (respiratory rate, heart rate,
and blood pressure) were evaluated before and
through 36 hours after each dose of study medica-
tion was administered. Pulse oximetry was moni-
tored continuously for 4 hours after FBT
placement, as well as any time the volunteers
attempted to sleep during the 12 hours after tablet
placement. In each treatment phase, the oral
mucosa was examined by the investigator 4 hours
after placement of FBT.
Statistical Analyses
The sample size of volunteers was not based on a
statistical power calculation but reﬂects the typical
number of volunteers enrolled in pharmacokinetic
studies. Descriptive statistics were used to summa-
rize the pharmacokinetic parameters for FBT by
dose. The slopes were obtained for natural log
(ln)-transformed pharmacokinetic parameters vs.
ln(dose). The primary methodology used to assess
dose proportionality from 100 mgt o8 0 0mg was a
comparison of the 90% conﬁdence interval (CI) of
the slopes with a criterion CI, based on a power
model [6]. A mixed-effect model was used on
ln-transformed AUC0–last, AUC0–•, and Cmax. The
model included ln-transformed dose, treatment
order, and period as ﬁxed effects, and intercept and
volunteer as random effects. The criterion interval
for testing the slope of the power model b=1
was as follows: [1 + (ln(0.80)/ln(high/low)], 1 +
[ln(1.25)/ln(high/low)], where high = 800 mg
(highest dose) and low = 100 mg (lowest dose). It
resulted in (0.8927, 1.1073). Dose proportionality
was concluded if the plot of pharmacokinetic
parameter vs. dose indicated linearity (i.e.,
slope = 1) and the 90% CI for the slope fell within
the range 0.8927 to 1.1073.
Analyses of variance were performed for pair-
wise comparisons on the dose-normalized and
ln-transformed AUC0–last, AUC0–•, and Cmax.
Treatment order, treatment, and period were ﬁxed
effects, and volunteer nested within treatment
order was a random effect. The statistical analyses
were performed with SAS PROC MIXED
software.
In the post hoc analysis, the same statistical
analysis model for dose proportionality used on
AUC0–• and AUC0–last was applied to the partial
AUC values for AUC0–8, AUC0–12, AUC0–18, and
AUC0–24.
The pharmacokinetic population comprised
volunteers who completed 2 periods of the study.
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prised all volunteers who received 1 dose of
FBT.
Results
Study Population
Twenty-ﬁve volunteers were enrolled in the study;
23 (2 men, 21 women) aged 20 to 51 years
(Table 1) were included in both the pharmacoki-
netic and safety populations, and 19 completed the
study. Six volunteers were discontinued from the
study: 4 because of withdrawal of consent (1 from
each treatment order) and 2 because of adverse
events (AEs) that occurred after naltrexone admin-
istration but before FBT administration. The
pharmacokinetic and safety analyses excluded the
2 volunteers who did not receive FBT.
Pharmacokinetic Findings
The mean serum fentanyl concentration-time
curves for FBT 100, 200, 400, and 800 mg are
illustrated in Figure 1. After the 100 and 200 mg
doses,serumfentanyldecreasedfrompeakconcen-
trations in a biphasic manner, but the later
portionsoftheseproﬁlestendedtofallbelowquan-
tiﬁable limits in some volunteers within 8 hours
after FBT administration and before the terminal
elimination phase was identiﬁable. Following the
400 and 800 mg doses, fentanyl concentrations
decreased from peak values in a triphasic manner.
Pharmacokinetic parameters for the fentanyl
doses are listed in Table 2. Tmax occurred at a
Figure 1 Mean (standard error of the
mean) serum fentanyl concentrations
after administration of FBT 100, 200,
400, and 800 mg.
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Table 1 Demographic variables
N = 23
Age, year (mean [SD]) 35 (8)
Sex, female (N [%]) 21 (91)
Weight, kg (mean [SD]) 57.4 (10.7)
Height, cm (mean [SD]) 162.3 (8.4)
Body mass index, kg/m
2 (mean [SD]) 21.8 (3.6)
SD = standard deviation.
Table 2 Pharmacokinetic parameters after a single dose of FBT 100, 200, 400, and 800 mg
Parameter
FBT dose
Statistic
100 mg 200 mg 400 mg 800 mg
(N = 21) (N = 21) (N = 22) (N = 21)
Cmax (ng/mL) Mean 0.45 0.91 1.62 2.99
SD 0.17 0.22 0.43 0.80
AUC0–• (ng·h/mL)* Mean 1.86 4.21 9.18 17.44
SD 0.47 0.95 2.24 3.88
AUC0–last (ng·h/mL) Mean 1.71 3.84 8.07 16.60
SD 0.45 0.81 1.93 3.80
tmax (min) Median 90 90 90 90
Range 30, 180 30, 180 30, 120 30, 180
t 1
2 (h)* Mean 2.60 5.56 10.44 10.06
SD 0.940 3.236 3.576 2.954
*N = 16, 19, 18, and 20 for 100, 200, 400, and 800 mg, respectively.
SD = standard deviation; Cmax = maximum observed serum fentanyl concentration; AUC0–• = area under the serum fentanyl concentration-time curve from time
zero to inﬁnity; AUC0–last = AUC0 to the time of the last quantiﬁable concentration; tmax = time to Cmax; t 1
2 = elimination half-life.
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all doses. Mean Cmax, AUC0–•, and AUC0–last
increased with increasing doses of FBT (Table 2,
Figure 2). Mean t 1
2of FBT increased with dose up
to 400 mg; however, for the 100 and 200 mg doses,
as previously stated, fentanyl concentrations fell
below quantiﬁable limits early, which prohibited
accurate estimation of the terminal t 1
2. Mean
t 1
2did not increase for the 400 to 800 mg doses of
FBT.
FBT Dose Proportionality
Statistical analysis showed that the slopes of
the plots for ln-transformed Cmax, AUC0–•, and
AUC0–last vs. ln-transformed dose were all close to
1, but the 90% CIs of the slopes were not com-
pletely contained within the predeﬁned range for
dose proportionality (0.8927, 1.1073). The slopes
(90% CIs) were 0.9118 (0.8601, 0.9635) for Cmax,
1.0756 (1.0377, 1.1136) for AUC0–•, and 1.0992
(1.0677, 1.1307) for AUC0–last. Dose proportional-
ity was not observed by analysis of variance
performed for pairwise comparisons on ln-
transformed and dose-normalized AUC0–last,
AUC0–•, and Cmax.
The statistical analysis may have failed to show
dose proportionality because, since serum fentanyl
levels fell below the limit of quantitation after 18
hours after the administration of FBT 100 mg and
200 mg in some volunteers, AUC0–•, AUC0–last, and
t 1
2values were probably underestimated. For this
reason, a post hoc analysis was performed on
partial AUCs.
In the post hoc analysis of partial AUCs, the
criteria for dose proportionality were met. The
slopes of ln-transformed AUC vs. ln-transformed
dose were close to 1 and their 90% CIs fell within
thepredeﬁnedrangerequiredfordoseproportion-
ality: AUC0–8 (slope = 0.95 [90% CI = 0.9188,
0.9737]), AUC0–12 (0.96 [0.9323, 0.9873]), AUC0–18
(0.99 [0.9567, 1.0135]), and AUC0–24 (1.01 [0.9823,
1.0423]). An analysis of variance was also per-
formed for pairwise comparisons on ln-
transformed and dose-normalized AUC0–8,
AUC0–12, AUC0–18, and AUC0–24. Dose propor-
tionality was found for AUC0–18 and AUC0–24, but
not for AUC0–8 or AUC0–12 over the 100 to 800 mg
dose range.
Buccal DwellTime
The mean buccal dwell times for FBT were 48.95,
59.24, 59.27, and 68.14 minutes for the 100, 200,
400, and 800 mg doses, respectively.
Safety andTolerability
As stated previously, naltrexone was administered
to these healthy volunteers to minimize the
opioid effects of fentanyl. In the safety analysis
set, 18 volunteers had 1 AE, and all AEs were
mild or moderate. No volunteers in the safety
analysis set had serious AEs or discontinuations
resulting from AEs. The most frequent AEs are
summarized in Table 3. One report of gingival
pain (200 mg dose) was the only AE associated
with the oral mucosa, and it was considered by
the investigator to be related to the study
regimen. There was no evidence of a relationship
between AEs and FBT dose, except for dizziness,
which was reported more frequently at the
800 mg dose. A single report of vasovagal syncope
was not considered by the investigator to be
related to the study drug. There were no clini-
cally signiﬁcant changes in laboratory measures,
ECG parameters, or physical examination ﬁnd-
ings from screening to the end of the study, nor
were there any signiﬁcant changes in vital signs at
2 hours (time point close to the median tmax of 90
minutes) or 4 hours after administration of any of
the doses.
Table 3 Adverse events occurring in 5% of volunteers at any dose of FBT 100 mgt o8 0 0mg*
Adverse event
FBT dose
100 mg 200 mg 400 mg 800 mg Total
(N = 21) (N = 21) (N = 22) (N = 21) (N = 23)
N (%) N (%) N (%) N (%) N (%)
Dizziness 2 (9.5) 2 (9.5) 2 (9.1) 4 (19.0) 8 (34.8)
Dyspepsia 2 (9.5) 3 (14.3) 1 (4.5) 2 (9.5) 5 (21.7)
Headache 2 (9.5) 1 (4.8) 3 (13.6) 2 (9.5) 6 (26.1)
Nausea 3 (14.3) 4 (19.0) 2 (9.1) 2 (9.5) 9 (39.1)
Somnolence 1 (4.8) 2 (9.5) 2 (9.1) 2 (9.5) 6 (26.1)
Vomiting 0 (0) 3 (14.3) 1 (4.5) 0 (0) 3 (13.0)
*Volunteers who had multiple episodes of a given adverse event during a treatment phase are counted once.
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The primary objective of this study was to evalu-
ate the dose proportionality of fentanyl Cmax,
AUC0–last, and AUC0–• across the dose range of
FBT 100 to 800 mg in healthy Japanese volunteers.
These parameters appeared to be approximately
dose proportional, though they did not meet the
statistical criteria for dose proportionality. Post
hoc analysis of partial areas from time zero to
serum sampling times at 8, 12, 18, and 24 hours
(AUC0–8, AUC0–12, AUC0–18, and AUC0–24) showed
that all of these truncated areas were proportional
to dose. The mean buccal dwell times for FBT
ranged from 49 to 68 minutes; however, no asso-
ciation has been found between variations in dwell
time and FBT pharmacokinetic parameters and
early exposure as measured by Cmax,t max, and
AUC0–tmax′ [7].
Safety and tolerability ﬁndings would not be
expected to reﬂect those in patients because the
healthy volunteers in this study were administered
oral naltrexone to minimize the opioid effects of
fentanyl. All AEs were mild or moderate. The
most common AEs were nausea, dizziness, head-
ache, somnolence, dyspepsia, and vomiting, a
ﬁnding similar to that previously reported in
healthy volunteers administered FBT and naltrex-
one [3,8–10].
A number of elements intrinsic to open-label
studies in healthy individuals limit the interpreta-
tion of results, such as differences in drug metabo-
lism in healthy persons compared with patients
who have medical conditions, such as hepatic or
renal impairment. Unlike healthy individuals,
patients with chronic medical conditions may be
taking multiple pharmacologic therapies that
could alter drug metabolism.
In conclusion, although the primary results
from this study did not meet the statistical criteria
for dose proportionality over the FBT dose range
of 100 to 800 mg, a post hoc analysis examining
AUCs for 0–8, 0–12, 0–18, and 0–24 hours sup-
ported dose proportionality.
Acknowledgments
Corresponding Author: Mona Darwish, PhD, Cepha-
lon, Inc., 41 Moores Road, Frazer, PA 19355, USA. Tel:
(610) 738-6417; Fax: (610) 738-6396; E-mail:
mdarwish@cephalon.com
Conﬂict of Interest: All authors are current or former
employees or contractors of Cephalon, Inc. We thank
Richard D. Wasnich, MD and the staff at Radiant
0
0.5
1
1.5
2
2.5
3
3.5
0 100 200 300 400 500 600 700 800
Theoretical,
slope = 1
FBT Dose ( g)
C
m
a
x
 
(
n
g
/
m
L
)
A
0
5
10
15
20
0 100 200 300 400 500 600 700 800
FBT Dose ( g)
A
U
C
0
-
l
a
s
t
 
(
n
g
￿
h
/
m
L
)
B
Theoretical,
slope = 1
0
5
10
15
20
0 100 200 300 400 500 600 700 800
FBT Dose ( g)
A
U
C
0
-
 
(
n
g
￿
h
/
m
L
)
C
Theoretical,
slope = 1
Figure 2 Relationship between mean (standard error of
the mean) Cmax (A), AUC0–last (B), and AUC0–• (C) vs. Dose
of FBT. For dose proportionality, the prespeciﬁed bounds
for the 90% CIs of the slopes were 0.8927 to 1.1073. The
slopes (90% CI) were 0.9118 (0.8601, 0.9635) for Cmax,
1.0756 (1.0377, 1.1136) for AUC0–•, and 1.0992 (1.0677,
1.1307) for AUC0–last. AUC0–last = area under the serum fen-
tanyl concentration-time curve (AUC) from time zero to the
last quantiﬁable concentration; AUC0–• = AUC0 to inﬁnity;
Cmax = maximum observed serum fentanyl concentration.
48 Darwish et al.
Arch Drug Info 2008;1:43–49Research for their help in the conduct of this study.
Embryon, Inc. received ﬁnancial support from
Cephalon for writing and editorial assistance for this
manuscript.
References
1 Fentora [prescribing information]. Frazer, PA:
Cephalon, Inc.; 2007.
2 Durfee S, Messina J, Khankari R. Fentanyl effer-
vescent buccal tablets. Am J Drug Deliv 2006;
4:1–5.
3 Darwish M, Kirby M, Robertson P Jr, Tracewell W,
Jiang JG. Pharmacokinetic properties of fentanyl
effervescent buccal tablets: A phase I, open-label,
crossover study of single-dose 100, 200, 400, and
800 mg in healthy adult volunteers. Clin Ther
2006;28:707–14.
4 Tateishi T, Krivoruk Y, Ueng YF, Wood AJ,
Guengerich FP, Wood M. Identiﬁcation of human
liver cytochrome P-450 3A4 as the enzyme respon-
sible for fentanyl and sufentanil N-dealkylation.
Anesth Analg 1996;82:167–72.
5 Adams M, Pieniaszek HJ Jr, Gammaitoni AR,
Ahdieh H. Oxymorphone extended release does not
affect CYP2C9 or CYP3A4 metabolic pathways.
J Clin Pharmacol 2005;45:337–45.
6 Smith BP, Vandenhende FR, DeSante KA, Farid
NA, Welch PA, Callaghan JT, et al. Conﬁdence
interval criteria for assessment of dose proportion-
ality. Pharm Res 2000;17:1278–83.
7 Darwish M, Kirby M, Jiang JG. Effect of buccal
dwell time on the pharmacokinetic proﬁle of fenta-
nyl buccal tablet. Expert Opin Pharmacother
2007;8:2011–6.
8 Darwish M, Kirby M, Robertson P, Hellriegel E,
Jiang JG. Comparison of equivalent doses of fenta-
nyl buccal tablets and arteriovenous differences in
fentanyl pharmacokinetics. Clin Pharmacokinet
2006;45:843–50.
9 Darwish M, Kirby M, Robertson P Jr, Hellriegel E,
Jiang JG. Single-dose and steady-state pharmacoki-
netics of fentanyl buccal tablet in healthy volunteers.
J Clin Pharmacol 2007;47:56–63.
10 Darwish M, Tempero K, Kirby M, Thompson J.
Relative bioavailability of the fentanyl effervescent
buccal tablet (FEBT) 1,080 mg versus oral transmu-
cosal fentanyl citrate 1,600 mg and dose proportion-
ality of FEBT 270 to 1,300 mg: A single-dose,
randomized, open-label, three-period study in
healthyadultvolunteers.ClinTher2006;28:715–24.
Dose Proportionality of FBT 49
Arch Drug Info 2008;1:43–49